合成乳腺X线联合DBT与全视野数字乳腺X线联合DBT的前瞻性比较:召回分歧可能影响癌症检出
前瞻性研究纳入1022例患者,比较SM+DBT与FFDM+DBT的召回率、癌症检出率、PPV1及召回分歧。两组召回率7.3% vs 7.9%,癌症检出率6.8 vs 7.8/1000,PPV1 9.3% vs 9.9%,差异均无统计学意义。SM+DBT漏诊1例钙化癌,19例召回分歧中68%与钙化有关,提示钙化召回分歧可能影响癌症检出。
要点
- SM+DBT与FFDM+DBT在召回率、癌症检出率及PPV1上无显著差异。
- SM+DBT漏诊1例以钙化为表现的癌症,需警惕钙化评估。
- 召回分歧主要涉及钙化(68%),阅片时应注意钙化征象的差异。
诊断标准与关键数值
- 召回率:SM+DBT 7.3%,FFDM+DBT 7.9%(差值-0.6%,90% CI -1.4%至0.1%)。
- 癌症检出率:SM+DBT 6.8/1000,FFDM+DBT 7.8/1000(差值-1.0,95% CI -5.5至2.8,p=0.317)。
- PPV1:SM+DBT 9.3%,FFDM+DBT 9.9%(相对PPV 0.95,95% CI 0.73-1.22,p=0.669)。
- FFDM+DBT检出8例癌症,SM+DBT检出7例(漏诊1例钙化癌)。
- 19例患者召回分歧,其中68%(13/19)涉及钙化;SM+DBT召回6例FFDM+DBT未召回的钙化,FFDM+DBT召回7例SM+DBT未召回的钙化。
临床应用与阅片要点
- 在日常阅片中,SM+DBT对钙化的评估可能与FFDM+DBT存在差异,需仔细对照。
- 报告钙化时应注意描述其形态和分布,以减少漏诊。
- 对于钙化可疑病例,可考虑结合FFDM+DBT或进一步影像检查。
局限性
- 单中心前瞻性研究,样本量1022例,可能限制普遍性。
- 8名放射科医生序贯解读,可能存在阅读顺序偏倚。
- 召回分歧分析样本量小(19例),需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: Synthesized mammography with digital breast tomosynthesis (SM+DBT) and full-field digital mammography with DBT were prospectively evaluated for recall rate (RR), cancer detection rate (CDR), positive predictive value 1 (PPV1), lesion recall differences, and disagreements in recall for additional imaging.
MATERIALS AND METHODS: From December 15, 2015 to January 15, 2017, after informed consent was obtained for this Health Insurance Portability and Accountability Act compliant study, each enrolled patient's SM+DBT and FFDM+DBT were interpreted sequentially by one of eight radiologists. RR, CDR, PPV1, and imaging findings (asymmetry, focal asymmetry, mass, architectural distortion, and calcifications) recalled were reviewed.
RESULTS: For SM+DBT and FFDM+DBT in 1022 patients, RR was 7.3% and 7.9% (SM+DBT vs. FFDM+DBT: diff= -0.6%; 90% CI= -1.4%, 0.1%); CDR was 6.8 and 7.8 per 1000 (SM+DBT vs. FFDM+DBT: diff= -1.0, 95% CI= -5.5, 2.8, p = 0.317); PPV1 was 9.3% and 9.9% (relative positive predictive value for SM+DBT vs. FFDM+DBT: 0.95, 95% CI: 0.73-1.22, p = 0.669). FFDM+DBT detected eight cancers; SM+DBT detected seven (missed 1 cancer with calcifications). SM+DBT and FFDM+DBT disagreed on patient recall for additional imaging in 19 patients, with majority (68%, 13/19 patients) in the recall of patients for calcifications. For calcifications, SM+DBT recalled six patients that FFDM+DBT did not recall, and FFDM+DBT recalled seven patients that SM+DBT did not recall, even though the total number of calcifications finding recalled was similar overall for both SM+DBT and FFDM+DBT.
CONCLUSION: Disagreement in recall of patients for calcifications may impact cancer detection by SM+DBT, warranting further investigation.
引用
- Huang ML, Hess K, Ma J, et al. Prospective Comparison of Synthesized Mammography with DBT and Full-Field Digital Mammography with DBT Uncovers Recall Disagreements That may Impact Cancer Detection. Acad Radiol. 2021. PMID: 34538550. doi:10.1016/j.acra.2021.08.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。